GeoVax Labs, Inc. has announced the expansion of its oncology development strategy to include assessments of additional solid tumor targets for Gedeptin®, its gene-directed enzyme prodrug therapy. The clinical-stage biotechnology company is working with the Winship Cancer Institute of Emory University to evaluate Gedeptin in combination with immune checkpoint inhibitors in preclinical models of several solid tumor types beyond head and neck cancer.
The expansion initiative builds on checkpoint inhibitor momentum and follows landmark KEYNOTE-689 results that demonstrated the transformative potential of neoadjuvant checkpoint therapy in head and neck cancer. GeoVax is specifically evaluating Gedeptin's mechanism—localized intratumoral cytotoxicity that also primes systemic immune responses—in tumor settings such as triple negative breast cancer and cutaneous malignancies. This strategic move addresses a critically important area of solid tumor cancer therapy and represents a major value-creation opportunity for the company.
GeoVax previously announced updated plans for a Phase 2 clinical trial, AdPNP-203, which will evaluate the addition of intra-tumoral Gedeptin® and intravenous fludarabine to recently approved neoadjuvant pembrolizumab as first-line treatment of patients with head and neck squamous cell carcinoma eligible for curative surgery. The trial is designed to assess major pathological response and associated immunologic and biomarker outcomes following two pre-surgical cycles of therapy, as well as event-free survival over a one-year period. Trial initiation is planned for the second half of 2026.
The strategic rationale for expanding Gedeptin development centers on three key factors: checkpoint synergy, therapeutic expansion, and timely alignment with recent clinical advancements. Gedeptin directly debulks tumors and enhances immune visibility, positioning it as a potential force multiplier for checkpoint inhibitors. Success in these preclinical programs could support Gedeptin's clinical evaluation into additional solid tumors. The KEYNOTE-689 trial results underscore the urgency and timeliness of expanding combination approaches such as Gedeptin plus Keytruda into additional tumor types.
David A. Dodd, Chairman & CEO of GeoVax, emphasized the importance of this expansion, stating that leveraging the strengths of oncology advisors and validated checkpoint inhibitor backbones aims to demonstrate that Gedeptin's tumor-debulking and immune-priming effects can potentially improve outcomes in a broader range of solid tumor cancers. Dr. Kelly T. McKee, Chief Medical Officer, added that preclinical efforts will provide in-vivo proof of concept for expanding Gedeptin-checkpoint inhibitor combination therapy, ensuring the company remains positioned at the forefront of immuno-oncology innovation.
GeoVax anticipates early readouts from its preclinical modeling work, with results supporting the design of potential clinical trials in selected solid tumor indications. The company is targeting initiation of its Phase 2 clinical trial of Gedeptin in combination with Keytruda for head and neck cancer in the second half of 2026. Potential collaborative discussions continue, with expectations of partnership or collaboration relative to both clinical development and potential commercialization of Gedeptin. For more information about the company's clinical trials and updates, visit https://www.geovax.com.
